학술논문

Correction: Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 Week results of the SIMRIKI retrospective study (PLoS ONE (2016) 11:10 (e0164455) DOI: 10.1371/journal.pone.0164455)
Document Type
Erratum
Source
In: PLoS ONE. (PLoS ONE, 1 February 2017, 12(2))
Subject
Language
English
ISSN
19326203